We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- QOL Medical will acquire specialty pharmaceutical company Evoke Pharma for $11.00 per share in cash, representing a 139.7% premium to the most recent closing price. - The acquisition centers on GIMOTI, the first and only FDA-approved nasal spray formulation of metoclopramide for treating acute and recurrent diabetic gastroparesis in adults. - The transaction, unanimously approved by both boards of directors, is expected to close by the end of 2025 through a tender offer structure. - QOL Medical's deep experience in gastrointestinal disorders commercialization positions the company to expand GIMOTI's reach among patients and healthcare providers.
